Phase 3 Rare Disease Trial, Recruiting NCT02305654 Sponsor: Institute of Cancer Research, United Kingdom Condition: Rare Disease
Back to Rare Disease

Phase 3 Rare Disease Trial, Recruiting

NCT02305654
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part in the trial
  • Your cancer can be measured using standard imaging or assessment methods
  • Your cancer has been confirmed by a tissue biopsy to be squamous cell carcinoma (a specific type of cancer cell) of the penis
  • Your cancer has spread to nearby lymph nodes in the groin area (either one side or both sides, or the nodes are fixed in place), but has not spread to distant parts of the body
  • You are well enough to carry out daily activities, or have only mild limitations — roughly healthy enough to be up and about for most of the day

Who may not be able to join:

  • Your penile cancer is a specific rare type called pure verrucous carcinoma
  • Your penile cancer is a type other than squamous cell carcinoma
  • Your cancer started in the urethra (the tube that carries urine), rather than the penis itself
  • Your cancer has already spread to distant parts of the body (such as organs or distant lymph nodes)
  • You have previously had chemotherapy or a combination of chemotherapy and radiotherapy
  • You have had another cancer (other than certain common skin cancers) that needed treatment — surgical or otherwise — within the last 3 years (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Steve Nicholson, Mid and South Essex NHS Foundation Trust

Phone: 02087224261

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Institute of Cancer Research, United Kingdom
Registry
ClinicalTrials.gov
Start date
12 May 2017
Est. completion
31 May 2027

Where this trial is recruiting

🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov